Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Metrion Biosciences Ltd.. (4/8/19). "Press Release: Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer". Cambridge.

Organisations Organisation Metrion Biosciences Ltd.
  Organisation 2 CeNeS Pharmaceuticals plc (LSE: CEN)
  Today Paion UK Ltd.
  Group Paion (Group)
Products Product contract research (drugs)
  Product 2 drug discovery services
Persons Person Southan, Andrew (Metrion Biosciences 201904– promoted to CEO joined 201610 before CeNeS + Ionix + BioFocus)
  Person 2 McCullagh, Keith (Santaris Pharma 200506 CEO)

Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.

Dr Southan joined Metrion as Head of Commercial Operations in October 2016, was promoted to Chief Operating Officer in April 2017, and joined the board as a director in March 2018. During this period the Company has made significant progress, developing innovative, high-quality assays for its clients and expanding the international customer base into new territories.

Andy has over 25 years of experience in ion channel research and development, starting his career at Wyeth Research (UK), followed by postdoctoral studies at Imperial College London. He has also held leadership roles at CeNeS Pharmaceuticals and Ionix Pharmaceuticals, and spent 12 years leading and expanding the UK ion channel team for BioFocus and Charles River Laboratories.

Keith McCullagh. Chairman of Metrion Biosciences, commented: “Andy has been a driving force supporting Metrion’s growth and success over the past three years. His extensive pharmaceutical CRO industry experience, deep technical understanding of the ion channel field and strong management skills made him the ideal candidate for this new leadership role. I congratulate Andy on his appointment and look forward to working with him to achieve continued progress.”

Dr Andrew Southan, Chief Executive Officer, Metrion Biosciences, said: “It is a pleasure to work with Metrion’s team of expert ion channel specialists, management team and board of directors, and I am looking forward to this next chapter as CEO, further expanding Metrion’s ion channel services as well as the Company’s reputation as a global leader in ion channel biology.”


Photo: Dr Andrew Southan, Chief Executive Officer, Metrion Biosciences For a high resolution image please contact Zyme Communications

Media Contacts

Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 947

Keith McCullagh PhD
Chairman, Metrion Biosciences

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organisation and drug discovery business. The Company provides customers with access to a range of high quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences’ specialist ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimisation. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages. For more information, see:

Record changed: 2019-04-16


Picture [iito] Made Without Love 650x80px

More documents for Metrion Biosciences Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top